Drugs Made In America Acquisition II Corp. Ordinary Shares
DMII | NASDAQ
$10.20
$0.00 (0.00%)
At close: Oct 30, 2026, 3:59 PM ET
$10.19
-$0.01 (-0.10%)
After-hours:
Oct 30, 2026, 4:02 PM ET
Company Profile
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
Key Executives
| Name | Position |
|---|---|
| Roger Bendelac | Chief Executive Officer |
| Saleem Elmasri | CFO & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2026 | 10-Q | Quarterly Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| Apr 28, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 10-K | Annual Report |
| Apr 03, 2026 | 8-K | Current Report |
| Apr 01, 2026 | NT 10-K | Filing |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 06, 2026 | 8-K | Current Report |
| Mar 06, 2026 | 8-K | Current Report |
| Nov 18, 2025 | 10-Q | Quarterly Report |
Drugs Made In America Acquisition II Corp. Ordinary Shares
| Country | United States |
| IPO Date | Dec 4, 2025 |
| Industry | Financial - Conglomerates |
| Sector | Financial Services |
| Employees | 2 |
| CEO | Roger Bendelac |
Contact Details
420 Lexington Avenue New York,
New York 10170 United States
Stock Details
| Ticker Symbol | DMII |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002040475 |
| CUSIP Number | G2851K104 |
| ISIN Number | KYG2851K1040 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove DMII